{
    "clinical_study": {
        "@rank": "79161", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Assess the efficacy and toxicity of mexiletine in the management of paresthesias and\n      pain in patients with diabetic neuropathy."
        }, 
        "brief_title": "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy", 
        "completion_date": "February 1999", 
        "condition": [
            "Pain", 
            "Diabetic Neuropathies", 
            "Paresthesia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Neuropathies", 
                "Paresthesia"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double-blind study.  Patients are stratified by\n      participating institution.\n\n      The first group receives oral mexiletine 3 times a day for 6 weeks.  The dose is increased\n      after the first week if there are no side effects.\n\n      The second group receives a placebo. Patients cross to the alternate treatment after a\n      1-week washout."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients with painful diabetic neuropathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004647", 
            "org_study_id": "199/11702", 
            "secondary_id": "UTENN-4686"
        }, 
        "intervention": {
            "intervention_name": "mexiletine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Mexiletine"
        }, 
        "keyword": [
            "diabetic neuropathy", 
            "disease-related problem/condition", 
            "neurologic and psychiatric disorders", 
            "pain", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Tennessee", 
            "last_name": "Tulio Bertorini", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "citation": "Bertorini TE, Alzagatiti BI, Horner LH, et al.: Electrophysiological effects of mexiletine in painful neuropathy. Nerve 21(11): 1576, 1998."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004647"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Tennessee", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 1993", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1999"
    }, 
    "geocoordinates": {}
}